Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its manufacturing capacity of AllocetraTM, following the first confirmed coronavirus (COVID-19) case in Israel, in preparation for potential requests for treatment of coronavirus (COVID-19) patients who are hospitalized with diagnosed organ dysfunctions or failures related to coronavirus. AllocetraTM is an experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose lethal pathophysiology – cytokine storm followed by organ failure – is similar to that of the coronavirus (COVID-19). Sepsis is the 3rd leading cause of mortality in the United States.
Enlivex Therapeutics Ltd. (“Enlivex” or the “Company”) (ENLV) today announced that it has withdrawn its previously announced proposed underwritten public offering of ordinary shares due to market conditions. The Company currently believes that it is not in the best interest of its shareholders to raise equity capital in the current market environment. The Company remains well capitalized with cash and cash equivalents, together with short term deposits, of approximately $13.5 million as of September 30, 2019, which the Company believes will be sufficient to fund its current operations through the beginning of the second quarter of 2021.
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of an aggregate of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering, before deducting the placement agent's fees and other estimated offering expenses payable by the Company, are expected to be $8.0 million.
Nes-Ziona, Israel, Nov. 12, 2019 -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that company management will make a.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Nes-Ziona, March 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236) covering ALLOCETRATM, the company’s immunotherapy candidate. This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in Israel. Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing.
The Company intends to grant the underwriter an option for a period of 45 days to purchase up to an additional 15 percent of the number of Shares to be issued and sold in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds received from the offering of the Shares for clinical, regulatory, manufacturing and research and development activities, potential acquisitions and in-licensing, and other general corporate purposes. Aegis Capital Corp. will act as sole book-runner for the offering.
Enlivex announced on November 4, 2019 positive interim safety and efficacy data from an ongoing trial of off-the-shelf universal Allocetra in patients with severe sepsis. The interim analysis comparing the first six Allocetra-treated patients with 37 severe sepsis patients with equivalent source of infection and disease severity who were hospitalized at the same hospital, demonstrated the potential of single dose Allocetra infusion as therapy for prevention of sepsis-associated organ failure and mortality. Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated immune response to infection.
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced positive interim efficacy data from the Company’s ongoing Phase Ib clinical trial in patients with severe sepsis. The interim analysis is based on a dataset of 43 patients with severe sepsis, all hospitalized at Hadassah Medical Center, which is one of the largest and most prestigious hospitals in Israel. Six patients admitted to Hadassah’s intensive care unit with sepsis have been administered with off-the-shelf Allocetra (“OTS Allocetra”) upon their admission, while 37 patients were matched controls that received standard of care treatment during 2016-2019 but did not receive OTS Allocetra.
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced positive final safety and efficacy data from the Company’s completed Phase Ib clinical trial in patients with severe sepsis. The final analysis compared the clinical data of 10 patients admitted to the intensive care unit with sepsis who were administered off-the-shelf AllocetraTM (“Allocetra-OTS”) upon their admission, with 37 patients who were matched controls (matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection source) who received only the standard of care treatment at the same hospital during 2014-2019 but did not receive Allocetra-OTS.
Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share for aggregate gross proceeds of $8.0 million. The Company intends to use the net proceeds from the offering for clinical, regulatory, manufacturing and research and development activities, potential acquisitions and in-licensing, as well as for working capital and other general corporate purposes. A shelf registration statement on Form F-3 (File No. 333-232009) relating to the ordinary shares offered in the registered direct offering was filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2019 and declared effective by the SEC on June 21, 2019.
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA) selected the Company’s planned COVID-19 and sepsis clinical programs to receive, in the aggregate, a non-dilutive grant of approximately $1.5 million for the period through the first quarter of 2021. To date, Enlivex has received a total of approximately $4.31 million in grants from the IIA for its historical clinical trials and development. The IIA is an independent, publicly funded agency charged with fostering the development of industrial R&D within the State of Israel.
Companies In The News Are: WMGI, ENLV, CRNT, UAA
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that new analyses from its recently completed Phase Ib clinical trial of AllocetraTM in patients with sepsis will be presented as part of an oral presentation at the International Society for Cellular Therapy (ISCT) 2020 Paris-Virtual Annual Meeting at a plenary satellite entitled “Moving ahead at full speed: Immune-Mediated Therapeutics”. The presentation will include new exploratory endpoint analyses that demonstrated the potential of AllocetraTM to resolve cytokine storms with heterogenous underlying pathologies, as well as previously disclosed safety and efficacy data.
Nes-Ziona, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today confirmed the public statements made by the Head of Israel Economic and Commercial Mission to South Korea, regarding a proposal submitted by Enlivex and the Head of Israel Economic and Commercial Mission to South Korea to South Korean authorities with respect to the potential use of AllocetraTM as treatment of patients with Coronavirus (COVID-19) patients who are hospitalized in intensive care units and suffering from organ dysfunctions or failures. AllocetraTM is an experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose lethal pathophysiology – hyper stimulation of the immune response and cytokine storm followed by organ failure – that may be similar to that of the coronavirus (COVID-19) associated with the newly recognized virus SARS-CoV-2.
Nes-Ziona, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain accredited and healthcare-focused institutional investors, including Armistice Capital, for the purchase in a registered direct offering of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants will have an exercise price of $9.00 per ordinary share, an exercise period commencing immediately upon issuance and a term of two years.
Nes-Ziona, Israel, Feb. 20, 2020 -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a.
Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused institutional investors, including Armistice Capital, of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant, for aggregate gross proceeds of $16.75 million. The warrants have an exercise price of $9.00 per ordinary share, an exercise period commencing immediately upon issuance and a term of two years from the issuance date. As part of the offering, the Company agreed to a customary lock-up period of 75 days following the offering.
Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of AllocetraTM (formerly referred to as off-the-shelf AllocetraTM) in COVID-19 patients has commenced. “While work investigating the exact pathophysiology of COVID-19 is ongoing, recent publications have described the complications related to the virally induced COVID-19 disease as associated with organ dysfunction and cytokine storms, which are markedly similar to those observed in septic patients in the ICU,” said Prof. Vernon van Heerden, Head of the Critical Care Medicine Unit at Hadassah Hospital in Israel, and the lead investigator of both the COVID-19 trial and a recently-completed Phase Ib clinical trial of AllocetraTM in sepsis patients.